Teva Defends Vincristine Discontinuation Decision
Insists It Is Not Responsible For US Shortages
Amid emotive US mainstream media coverage of shortages of the children’s cancer treatment vincristine, Teva insists it is not to blame after discontinuing production of the chemotherapy agent.